Cipher Pharmaceuticals (TSE:CPH) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Cipher Pharmaceuticals announced that their partner, Moberg Pharma, reported disappointing results from a Phase 3 study of MOB-015, a nail fungus treatment, which did not meet its primary endpoint. Despite this setback, Cipher remains focused on its recent acquisition of the Natroba business and sees significant growth potential in the U.S. and international markets.
For further insights into TSE:CPH stock, check out TipRanks’ Stock Analysis page.
